个人简述:

我国每年约30万终末期肝病患者等待肝移植，而真正能接受手术的患者仅仅为0.6%，供肝短缺是制约肝移植发展最紧迫的问题。脂肪肝作为主要的边缘性供肝被很多单位采用来缓解供肝短缺。脂肪肝对缺血再灌注损伤比正常肝脏更为敏感，可能是造成脂肪供肝移植受者术后恢复能力差，甚至手术失败的主要原因。临床上尚没有合适的治疗方案减轻脂肪肝缺血再灌注损伤。因此深入研究脂肪肝缺血再灌注损伤的发生机制，并进一步探索其治疗对策，对于扩大供肝来源，提高肝移植手术的成功率、减少术后并发症的发生等均有着重要的意义。

科研工作:

1: Li C, Wang K, Guo L, Sun H, Huang H, Lin X, Li Q. Inhibition of miR-34a-5p alleviates hypoxia-reoxygenation injury by enhancing autophagy in steatotic hepatocytes. Biol Open. 2018 267(3). pii: bio033290. (第一作者兼通讯作者)2:Liu J, Hu X, Chen J, Li X, Wang L, Wang B, Peng W, Yang C, Li Z, Chen Y, Wang YJ, Li C, Li X, Yan F, Wang Y, Shang C, Wang X, Chen T, Huang P. Pericentral hepatocytes produce insulin-like growth factor-2 to promote liver regeneration during selected injuries in mice. Hepatology. 2017 66(6):2002-2015. 3: Li CJ, Li L. Tacrolimus in preventing transplant rejection in Chinese patients- optimizing use. Drug Des Devel Ther. 20159:473-485. eCollection 2015. (第一作者)4: Li CJ, Li L, Lin L, Jiang HX, Zhong ZY, Li WM, Zhang YJ, Zheng P, Tan XH, Zhou L. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS One. 2014 9(1):e86206. (第一作者)5: Chang Y, Yan W, He X, Zhang L, Li C, Huang H, Nace G, Geller DA, Lin J, Tsung A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012 143(1):177-187. 6: Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, Si-Tu B, Li ZH. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.Eur J Clin Pharmacol. 201167(8):787-95. (通讯作者)7: Li L, Li CJ, Zhang YJ, Zheng L, Jiang HX, Si-Tu B. Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay. Clin Biochem. 201144(5-6):418-22. (通讯作者)8：李川江,周杰. 肝细胞肝癌经肝动脉化疗栓塞联合索拉非尼降期后二期切除的初步报告[J]. 腹部外科,2017,30(04):295-298.9:李川江,邹衍泰,林建华,方学军,崔忠林,周杰. 保留半肝动脉血流的肝门阻断在肝细胞癌肝切除术中的应用[J]. 中华肝脏外科手术学电子杂志,2014,3(06):359-362.